Findings of a phase IIb clinical trial were released in ASCO 2020, EGFR T790M mutation‐positive advanced NSCLC patients treated with furmonertinib showed an ORR of 74.1% and PFS of 9.6 months.127. Here, EGFR is linked to non-small cell lung carcinoma.